Compare ACLS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | IDYA |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2000 | 2019 |
| Metric | ACLS | IDYA |
|---|---|---|
| Price | $86.34 | $32.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $101.50 | $51.21 |
| AVG Volume (30 Days) | 634.7K | ★ 724.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 3.80 | N/A |
| Revenue | ★ $839,048,000.00 | $218,710,000.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $7.91 | $191.08 |
| P/E Ratio | $22.23 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $40.40 | $13.45 |
| 52 Week High | $102.93 | $39.28 |
| Indicator | ACLS | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 45.04 |
| Support Level | $78.24 | $29.15 |
| Resistance Level | $91.51 | $33.64 |
| Average True Range (ATR) | 3.27 | 1.34 |
| MACD | 0.33 | -0.13 |
| Stochastic Oscillator | 74.46 | 41.56 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.